Ryeqo
relugolix / estradiol / norethisterone acetate
Table of contents
Overview
Ryeqo is a medicine used to treat moderate to severe symptoms of uterine fibroids (non-cancerous growths in the womb) in women of reproductive age.
Ryeqo contains the active substances relugolix, estradiol and norethisterone acetate.
-
List item
Ryeqo : EPAR - Medicine overview (PDF/121.19 KB)
First published: 29/07/2021
EMA/318437/2021 -
-
List item
Ryeqo : EPAR - Risk management plan summary (PDF/134.25 KB)
First published: 29/07/2021
Authorisation details
Product details | |
---|---|
Name |
Ryeqo
|
Agency product number |
EMEA/H/C/005267
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Therapeutic area (MeSH) |
Leiomyoma
|
Anatomical therapeutic chemical (ATC) code |
H01CC54
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Gedeon Richter Plc.
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
16/07/2021
|
Contact address |
Gyomroi ut 19-21 |
Product information
31/03/2023 Ryeqo - EMEA/H/C/005267 - PSUSA/00010942/202205
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pituitary and hypothalamic hormones and analogues
Therapeutic indication
Ryeqo is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.